{
    "doi": "https://doi.org/10.1182/blood.V106.11.5259.5259",
    "article_title": "CD34 Positive Cells Mobilized with Chemotherapy Plus Recombinant Human Growth Hormone (rhGH) and Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) Allows Sustained Engraftment in Previously Non-Mobilizer Patients. ",
    "article_date": "November 16, 2005",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "The availability of adequate amounts of peripheral blood progenitor cells (PBPC) is a prerequisite for the feasibility of high-dose therapy program in patients with neoplastic diseases. Due to prior chemio-radiotherapy or disease related factors, 20\u201330% of patients fails to mobilize sufficient amounts of PBPC. Therefore, non-mobilizer patients cannot complete their therapeutic program. The aims of the present study were: 1) to evaluate the combination rhGH+rhG-CSF after chemiotherapy as a mobilization regimen in previously non-mobilizers patients; 2) to assess safety and tolerability of rhGH+rhG-CSF treatment; 3) to evaluate hematopoietic recovery after reinfusion of rhGH+rhG-CSF mobilized PBPC. After informed consent, three patients (2 male, 1 female), that failed a previous mobilization cycle, were remobilized with chemotherapy plus rhGH (100\u03bcg/Kg/d, sc) and rhG-CSG (5\u03bcg/Kg/d, sc).  Case . Disease . TNC (x 108/Kg) . CD34+ (x 106/Kg) . CFC (x 106/Kg) . LTC-IC (x 104/Kg) . 1 LNH 8.5 7.6 5.68 15.9 2 LNH 18 6.2 3.57 5.0 3 MM 15 1.3 1.26 12.0 Case . Disease . TNC (x 108/Kg) . CD34+ (x 106/Kg) . CFC (x 106/Kg) . LTC-IC (x 104/Kg) . 1 LNH 8.5 7.6 5.68 15.9 2 LNH 18 6.2 3.57 5.0 3 MM 15 1.3 1.26 12.0 View Large No specific side effects were noticed due to rhGH treatment. Reinfusionof PBPC after myeloablative therapy resulted in hematopoietic recovery with 16, 9, 11 days respectively to reach an absolute neutrophil count \u2265 500/\u03bcl and 24, 15, 15 days respectively to reach a platelet count \u2265 50000/\u03bcl. Hematopoietic engraftment is complete and sustained with a follow-up of 18, 11 and 9 months, respectively. In conclusion our data confirm that the addition of rhGH to rhG-CSF allows mobilization and collection of PBPC in previously non-mobilizer patients, and therefore the programmed high-dose therapy program can be satisfactorily completed, with sustained hematopoietic recovery.",
    "topics": [
        "cd34 antigens",
        "cerebrospinal fluid",
        "chemotherapy regimen",
        "colony-stimulating factors",
        "engraftment",
        "granulocyte colony-stimulating factor",
        "recombinant human growth hormone",
        "adverse effects",
        "follow-up",
        "neoplasms"
    ],
    "author_names": [
        "Camillo Almici, MD",
        "Rosanna Verardi, PhD",
        "Piero Ferremi, MD",
        "Alessandro Re, MD",
        "Chiara Cattaneo, MD",
        "Emilio Ferrari, MD",
        "Simona Braga, PhD",
        "Giuseppe Rossi, MD",
        "Mirella Marini, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Camillo Almici, MD",
            "author_affiliations": [
                "Lab. For Stem Cells Manipulation and Cryopreservation, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Rosanna Verardi, PhD",
            "author_affiliations": [
                "Lab. For Stem Cells Manipulation and Cryopreservation, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Piero Ferremi, MD",
            "author_affiliations": [
                "Immunohematology and Trasfusion Medicine, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandro Re, MD",
            "author_affiliations": [
                "Hematology, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Chiara Cattaneo, MD",
            "author_affiliations": [
                "Hematology, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Emilio Ferrari, MD",
            "author_affiliations": [
                "Immunohematology and Trasfusion Medicine, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Simona Braga, PhD",
            "author_affiliations": [
                "Lab. For Stem Cells Manipulation and Cryopreservation, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Rossi, MD",
            "author_affiliations": [
                "Hematology, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mirella Marini, MD",
            "author_affiliations": [
                "Immunohematology and Trasfusion Medicine, Spedali Civili di Brescia, Brescia, Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-29T09:32:44",
    "is_scraped": "1"
}